Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers

Inclusion Criteria: * Men and women greater than or equal to 18 years of age; * A diagnosis of ovarian, lung (small cell or non-small cell) or bladder cancer requiring systemic chemotherapy * Participant receiving a chemotherapy regimen given in a 21 or 28-day cycle, including 1 or more of the following agents or class of agents: * Nucleoside analog, including gemcitabine and fluorouracil; * Carboplatin or cisplatin; * Anthracycline; or * Alkylating agent; * Participant experienced severe thrombocytopenia, defined as 2 platelet counts \<50 x 109/L measured at least 24 hours apart, during the qualifying chemotherapy cycle, of their current chemotherapy regimen * ECOG performance status \<=2 Exclusion Criteria: * Participant has experienced \>=Grade 2 CIT other than during the current chemotherapy treatment regimen within 6 months of Screening; * Participant has any history of hematologic malignancies, including leukemia, myeloma, myeloproliferative disease, lymphoma, or myelodysplastic diseases; * Participant has received \>2 previous lines of chemotherapy or is receiving whole brain radiation during the study treatment period; * Participant has a known medical history of genetic prothrombotic syndromes * Participant has a history of arterial or venous thrombosis within 3 months of screening; * Use of vitamin K antagonists; * Participant has previously received a thrombopoietin receptor agonist or recombinant human thrombopoietin for the treatment of CIT within 3 months of screening